<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113186</article-id><article-id pub-id-type="publisher-id">ACM-41272</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_94657301.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  内镜下胃粘膜下剥离术后切缘阳性患者肿瘤残留或复发的回顾性分析
  Retrospective Analysis of Residual or Recurrence of Tumor in Patients with Positive Margin after Endoscopic Submucosal Gastric Dissection
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>倩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>福国</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1301</fpage><lpage>1308</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本研究通过对内镜下胃粘膜下剥离术后切缘阳性患者肿瘤残留或复发的回顾性分析来探讨评估切缘阳性患者的残留/复发肿瘤的发生率及临床、病理特征，并探究增加残留/复发的风险的因素，避免不必要的手术。方法：对在青岛大学附属医院内镜中心行内镜下粘膜剥离术治疗1002例患者的临床及病理资料进行回顾性分析，并将58例标本切缘肿瘤阳性的患者分为有残留/复发肿瘤和无残留/复发肿瘤两组，比较临床病理特征。结果：1) 术后进行外科切除手术的16名患者中残留肿瘤/淋巴结转移的患者共8名；随访的45名患者有2名患者分别于7、21个月发现局部复发；最终统计包括淋巴结转移在内的肿瘤残留/复发率为17.2% (10/58)。2) 统计学分析显示切缘类型(P = 0.012)、组织分化类型(P = 0.001)以及浸润深度(P = 0.004)与肿瘤残留/复发显著相关。结论：内镜下胃粘膜下剥离术后肿瘤切缘阳性患者，若术后病理为基底切缘阳性、未分化组织学类型、粘膜下浸润，提示肿瘤残留/复发的高风险，建议追加外科手术。
    Objective: In this study, the incidence and clinicopathological characteristics of residual/recurrent tumors in patients with positive margin after Endoscopic Submucosal Dissection (ESD) of gastric carcinoma were evaluated by retrospective analysis of residual/recurrent tumors in patients with positive margin. Our analysis also looked at factors that increased the risk of residual/recurrence to avoid unnecessary surgery. Methods: We retrospectively analyzed the clinical and pathological data of 1002 patients after ESD in the Endoscopy Center of the Affiliated Hospital of Qingdao University. 58 patients with positive marginal tumors were divided into the residual/recurrent tumor group and the non-residual/recurrent tumor group. We compared the clinicopathological characteristics of the two groups. Results: 1) Surgical resection was performed in 8 of the 16 patients with residual tumor/lymph node metastases. Local recurrences were found in 2 of the 45 patients followed up at 7/21 months. The final rate of residual/recurrence including lymph node metastasis was 17.2% (10/58). 2) Statistical analysis showed that the type of surgical margin (P = 0.012), the type of tissue differentiation (P = 0.001) and the depth of invasion (P = 0.004) were significantly associated with tumor residual/recurrence. Conclusion: For patients with positive tumor margins after endoscopic submucosal dissection, additional surgery is recommended if the postoperative pathology shows positive basal margin submucosal infiltration of undifferentiated histological type, suggesting a high risk of tumor residual/recurrence. 
  
 
</p></abstract><kwd-group><kwd>早期胃癌，内镜切除，切缘阳性，肿瘤残留，复发, Early Gastric Cancer</kwd><kwd> Endoscopic Resection</kwd><kwd> Positive Margin</kwd><kwd> Residual Tumor</kwd><kwd> Recurrence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究通过对内镜下胃粘膜下剥离术后切缘阳性患者肿瘤残留或复发的回顾性分析来探讨评估切缘阳性患者的残留/复发肿瘤的发生率及临床、病理特征，并探究增加残留/复发的风险的因素，避免不必要的手术。方法：对在青岛大学附属医院内镜中心行内镜下粘膜剥离术治疗1002例患者的临床及病理资料进行回顾性分析，并将58例标本切缘肿瘤阳性的患者分为有残留/复发肿瘤和无残留/复发肿瘤两组，比较临床病理特征。结果：1) 术后进行外科切除手术的16名患者中残留肿瘤/淋巴结转移的患者共8名；随访的45名患者有2名患者分别于7、21个月发现局部复发；最终统计包括淋巴结转移在内的肿瘤残留/复发率为17.2% (10/58)。2) 统计学分析显示切缘类型(P = 0.012)、组织分化类型(P = 0.001)以及浸润深度(P = 0.004)与肿瘤残留/复发显著相关。结论：内镜下胃粘膜下剥离术后肿瘤切缘阳性患者，若术后病理为基底切缘阳性、未分化组织学类型、粘膜下浸润，提示肿瘤残留/复发的高风险，建议追加外科手术。</p></sec><sec id="s2"><title>关键词</title><p>早期胃癌，内镜切除，切缘阳性，肿瘤残留，复发</p></sec><sec id="s3"><title>Retrospective Analysis of Residual or Recurrence of Tumor in Patients with Positive Margin after Endoscopic Submucosal Gastric Dissection</title><p>Yue Liang, Qian Li, Hun Sun, Fuguo Liu<sup>*</sup></p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/69-1572057x5_hanspub.png" /></p><p>Received: Feb. 23<sup>rd</sup>, 2021; accepted: Mar. 11<sup>th</sup>, 2021; published: Mar. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/69-1572057x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: In this study, the incidence and clinicopathological characteristics of residual/recurrent tumors in patients with positive margin after Endoscopic Submucosal Dissection (ESD) of gastric carcinoma were evaluated by retrospective analysis of residual/recurrent tumors in patients with positive margin. Our analysis also looked at factors that increased the risk of residual/recurrence to avoid unnecessary surgery. Methods: We retrospectively analyzed the clinical and pathological data of 1002 patients after ESD in the Endoscopy Center of the Affiliated Hospital of Qingdao University. 58 patients with positive marginal tumors were divided into the residual/recurrent tumor group and the non-residual/recurrent tumor group. We compared the clinicopathological characteristics of the two groups. Results: 1) Surgical resection was performed in 8 of the 16 patients with residual tumor/lymph node metastases. Local recurrences were found in 2 of the 45 patients followed up at 7/21 months. The final rate of residual/recurrence including lymph node metastasis was 17.2% (10/58). 2) Statistical analysis showed that the type of surgical margin (P = 0.012), the type of tissue differentiation (P = 0.001) and the depth of invasion (P = 0.004) were significantly associated with tumor residual/recurrence. Conclusion: For patients with positive tumor margins after endoscopic submucosal dissection, additional surgery is recommended if the postoperative pathology shows positive basal margin submucosal infiltration of undifferentiated histological type, suggesting a high risk of tumor residual/recurrence.</p><p>Keywords:Early Gastric Cancer, Endoscopic Resection, Positive Margin, Residual Tumor, Recurrence</p><disp-formula id="hanspub.41272-formula37"><graphic xlink:href="//html.hanspub.org/file/69-1572057x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/69-1572057x8_hanspub.png" /> <img src="//html.hanspub.org/file/69-1572057x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>我国是胃癌的高发地区，据统计中国胃癌死亡人数占癌症相关总死亡人数的13.6% [<xref ref-type="bibr" rid="hanspub.41272-ref1">1</xref>]。随着高清晰度白光内镜、色素内镜、窄带成像和放大内镜的广泛应用，早期胃癌及癌前病变的检出率逐渐提高。检出上皮内瘤变和早期胃癌的患者，建议立即结合色素内镜进行高质量的内镜评估并进行内镜下切除 [<xref ref-type="bibr" rid="hanspub.41272-ref2">2</xref>]。</p><p>相比于传统外科手术，内镜下切除保留了胃的生理解剖结构，具有创伤小、并发症少、恢复快、费用低的特点 [<xref ref-type="bibr" rid="hanspub.41272-ref3">3</xref>]。内镜粘膜切除术(Endoscopic Mucosal Resection, EMR)和内镜下粘膜剥离术(Endoscopic Submucosal Dissection, ESD)是常见的内镜下切除治疗手段。多项研究表明，ESD对病变的整块切除率高于EMR [<xref ref-type="bibr" rid="hanspub.41272-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref5">5</xref>]。为达到根治肿瘤的目的，要求对肿瘤进行根治性切除，而根治性切除的条件之一即为切缘阴性 [<xref ref-type="bibr" rid="hanspub.41272-ref6">6</xref>]。切缘阴性要求水平切缘(又称侧切缘)和垂直切缘(又称基底切缘)均为阴性。内镜下切除肿瘤后若存在切缘阳性，可能存在残留、复发以及淋巴结或远处转移的风险。多项研究显示，切缘阳性是胃ESD术后残留、追加手术及局部复发的危险因素 [<xref ref-type="bibr" rid="hanspub.41272-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref9">9</xref>]。当病变存在切缘阳性，即可归类为内镜的根治度C (eCuraC)，但对于eCuraC的早期胃癌病例的治疗策略，目前没有明确共识 [<xref ref-type="bibr" rid="hanspub.41272-ref6">6</xref>]。切缘阳性的病例进行外科胃切除手术后，并非所有手术标本均发现残留肿瘤 [<xref ref-type="bibr" rid="hanspub.41272-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref11">11</xref>]。有研究指出，对于切缘阳性但无淋巴结转移或粘膜下深部侵犯且无法手术治疗的早期胃癌病例，可考虑进行额外的内镜治疗或密切监测 [<xref ref-type="bibr" rid="hanspub.41272-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref13">13</xref>]。因此，本研究的目的是评估胃ESD术后肿瘤切缘阳性患者的残留/复发肿瘤的发生率及临床、病理特征，并探究增加残留/复发的风险的因素，避免不必要的手术。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 材料</title><p>2011年1月至2020年10月在青岛大学附属医院内镜中心行内镜下粘膜剥离术治疗患者的临床及病理资料。病理标本的侧切缘或垂直切缘为阳性的患者被纳入研究。本研究经伦理委员会批准，按照赫尔辛基宣言进行。</p></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. ESD过程</title><p>双通道内窥镜先端部带透明帽进镜定位病灶，然后结合窄带成像及靛胭脂染色来确定病灶边界。用高频电切装置于边界外5 mm进行标记。标记后用美兰、生理盐水、玻璃酸钠混合物溶液进行黏膜下注射以提升黏膜。用高频电切装置贴近肌层表面逐步行圆周切口和粘膜下层剥离，辨认血管并电凝预防出血，活动性出血点用电凝止血钳电凝止血，将病灶完整剥离切除。全切除后，对创面边缘血管进行预防性凝血并用和谐夹夹闭创面。</p></sec><sec id="s6_2_2"><title>2.2.2. 病理检查</title><p>将切除的标本进行拉伸、10%福尔马林固定，固定标本每隔2 mm进行切片，石蜡包埋后行苏木精和伊红染色，进行组织病理学检查。内镜下单个病灶切除被定义为整块切除；非整块切除的标本被尽可能精确地重建。侧切缘和/或垂直切缘出现不典型细胞(低级别上皮内瘤变、高级别上皮内瘤变或肿瘤细胞)认定为切缘阳性。因挤压或烧伤损伤而无法评估的病灶边缘也被认定为切缘阳性。</p></sec><sec id="s6_2_3"><title>2.2.3. 资料收集</title><p>回顾分析在组织学确认切除标本后获得的患者数据，资料包括：年龄、性别、胃癌家族史、烟酒史、肿瘤位置(长轴、短轴)、宏观类型、肿瘤大小、分化程度、浸润深度、溃疡、整块切除等。依据日本胃肠病学内窥镜学会/日本胃癌协会最新指南 [<xref ref-type="bibr" rid="hanspub.41272-ref6">6</xref>] 中关于ESD术后肿瘤可治愈性的评估，建议达到eCuraC的病例进行额外胃切除术，然而，一些高龄、严重共患病或拒绝手术的患者进行密切随访。</p></sec><sec id="s6_2_4"><title>2.2.4. 统计分析</title><p>采用SPSS 22.0统计软件对数据进行统计分析，对各组变量之间的差异，连续变量应用独立样本的t检验，分类变量应用卡方检验及秩和检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者的临床病程、病理特点</title><p>共有1002名患者因早期胃癌及癌前病变接受了内镜粘膜下剥离术，这些患者术后切除病灶中81例病灶切缘为阳性。如图1所示，在81名患者中，20名患者最初失访；16名患者进行外科切除手术，外科手术后病理提示残留肿瘤和/或淋巴结转移的患者共8名；45名患者定期接受内窥镜检查随访，随访期间有3名患者术后发生异时性胃癌，有2名患者分别于7、21个月时因局部复发接受第2次ESD治疗。除最初失访及异时性胃癌的患者外，最终纳入58例患者，包括淋巴结转移在内的肿瘤残留/复发率为17.2% (10/58)。</p><p>图1. 纳入分析的患者流程图</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of patients with positive margins and residual/recurrent case</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >残留/ 复发</th><th align="center" valign="middle" >淋巴结 转移</th><th align="center" valign="middle" >切缘 阳性</th><th align="center" valign="middle" >分化 程度</th><th align="center" valign="middle" >肿瘤定位(长轴)</th><th align="center" valign="middle" >肿瘤定位(短轴)</th><th align="center" valign="middle" >肉眼分型</th><th align="center" valign="middle" >肿瘤大小(mm)</th><th align="center" valign="middle" >合并溃疡</th><th align="center" valign="middle" >浸润深度</th><th align="center" valign="middle" >复发时间(月)</th><th align="center" valign="middle"  colspan="2"  >额外治疗</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >印戒细胞癌</td><td align="center" valign="middle" >下</td><td align="center" valign="middle" >小弯侧</td><td align="center" valign="middle" >隆起型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >下</td><td align="center" valign="middle" >前壁</td><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >下</td><td align="center" valign="middle" >小弯侧</td><td align="center" valign="middle" >隆起型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >粘膜下(SM2)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >下</td><td align="center" valign="middle" >前壁</td><td align="center" valign="middle" >凹陷型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜下(SM2)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >上</td><td align="center" valign="middle" >小弯侧</td><td align="center" valign="middle" >凹陷型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >均阳</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >上</td><td align="center" valign="middle" >小弯侧</td><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >残留</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >中</td><td align="center" valign="middle" >小弯侧</td><td align="center" valign="middle" >隆起型</td><td align="center" valign="middle" >&gt;2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜下(SM2)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >印戒细胞癌</td><td align="center" valign="middle" >下</td><td align="center" valign="middle" >大弯侧</td><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >外科手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >复发</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >基底</td><td align="center" valign="middle" >低分化腺癌</td><td align="center" valign="middle" >中</td><td align="center" valign="middle" >前壁</td><td align="center" valign="middle" >凹陷型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜下(SM1)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >ESD术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >复发</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >水平</td><td align="center" valign="middle" >中分化腺癌</td><td align="center" valign="middle" >中</td><td align="center" valign="middle" >大弯侧</td><td align="center" valign="middle" >混合型</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >粘膜内(M)</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >ESD术</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 切缘阳性并发生残留/复发的病例的特点</p><p>水平、垂直或两种切除边缘阳性的病例分别为29例、25例和4例。对无残留/复发组与残留/复发组病变病理特征进行比较，得出以下结论：两组病变均以下三分之一位置、小弯侧更常见。我院行胃ESD治疗的患者多符合我国指南的绝对/相对适应症，因此两组病变均达到较高的整块切除率，肿瘤直径均以≤2 cm为主。与无残留/复发组相比，残留/复发组中基底切缘阳性、低分化腺癌、粘膜下病变在组内所占百分比更高，分别为80%、70%、90%。残留/复发组合并溃疡的比例略多于无残留/复发组。所有纳入的患者中，仅在ESD术后随即行外科手术的患者发现2例淋巴结转移(表1，表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Statistical analysis of residual or recurrence of tumor in patients with positive margin after ES</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >潜在危险因素</th><th align="center" valign="middle" >无残留/复发[N = 48 (%)]</th><th align="center" valign="middle" >残留/复发[N = 10 (%)]</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >62.25 &#177; 8.34</td><td align="center" valign="middle" >59.80 &#177; 6.56</td><td align="center" valign="middle" >0.387</td></tr><tr><td align="center" valign="middle" >性别 男 女</td><td align="center" valign="middle" >34 (70.8) 14 (29.2)</td><td align="center" valign="middle" >9 (90.0) 1 (10.0)</td><td align="center" valign="middle" >0.389</td></tr><tr><td align="center" valign="middle" >胃癌家族史</td><td align="center" valign="middle" >11 (22.9)</td><td align="center" valign="middle" >0 (0.00)</td><td align="center" valign="middle" >0.216</td></tr><tr><td align="center" valign="middle" >吸烟史 无 有 已戒烟</td><td align="center" valign="middle" >26 (54.2) 18 (37.5) 4 (8.3)</td><td align="center" valign="middle" >3 (30.0) 6 (60.0) 1 (10.0)</td><td align="center" valign="middle" >0.361</td></tr><tr><td align="center" valign="middle" >饮酒史 无 有 已戒酒</td><td align="center" valign="middle" >26 (54.2) 17 (35.4) 5 (10.4)</td><td align="center" valign="middle" >3 (30.0) 5 (50.0) 2 (20.0)</td><td align="center" valign="middle" >0.354</td></tr><tr><td align="center" valign="middle" >切缘类型 水平 基底 均阳性</td><td align="center" valign="middle" >28 (58.3) 17 (35.4) 3 (6.3)</td><td align="center" valign="middle" >1 (10) 8 (80) 1 (10)</td><td align="center" valign="middle" >0.012<sup>* </sup></td></tr><tr><td align="center" valign="middle" >肿瘤位置(长轴) 上 中 下</td><td align="center" valign="middle" >10 (20.8) 2 (4.2) 36 (75.0)</td><td align="center" valign="middle" >2 (20.0) 3 (30.0) 5 (50.0)</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >肿瘤位置(短轴) 大弯侧 小弯侧 前壁 后壁</td><td align="center" valign="middle" >7 (14.6) 22 (45.8) 9 (18.8) 10 (20.8)</td><td align="center" valign="middle" >2 (20.0) 5 (50.0) 3 (30.0) 0 (0.00)</td><td align="center" valign="middle" >0.220</td></tr><tr><td align="center" valign="middle" >肉眼分型 隆起型 平坦型 凹陷型 混合型</td><td align="center" valign="middle" >13 (27.1) 2 (4.2) 18 (37.5) 15 (31.3)</td><td align="center" valign="middle" >3 (30.0) 0 (0.00) 3 (30.0) 4 (40.0)</td><td align="center" valign="middle" >0.777</td></tr><tr><td align="center" valign="middle" >分化类型 低级别上皮内瘤变 高级别上皮内瘤变 高分化腺癌 中分化腺癌 低分化腺癌 印戒细胞癌</td><td align="center" valign="middle" >11 (22.9) 3 (6.3) 11 (22.9) 10 (20.8) 10 (20.8) 3 (6.3)</td><td align="center" valign="middle" >0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 7 (70.0) 2 (20.0)</td><td align="center" valign="middle" >0.001<sup>* </sup></td></tr><tr><td align="center" valign="middle" >整块切除</td><td align="center" valign="middle" >46 (95.8)</td><td align="center" valign="middle" >10 (100.0)</td><td align="center" valign="middle" >0.380</td></tr><tr><td align="center" valign="middle" >肿瘤大小 ≤2 cm &gt;2 cm</td><td align="center" valign="middle" >39 (81.2) 9 (18.8)</td><td align="center" valign="middle" >9 (90.0) 1 (10.0)</td><td align="center" valign="middle" >0.509</td></tr><tr><td align="center" valign="middle" >浸润深度 粘膜内 粘膜下</td><td align="center" valign="middle" >29 (60.4) 19 (39.6)</td><td align="center" valign="middle" >1 (10.0) 9 (90.0)</td><td align="center" valign="middle" >0.004<sup>* </sup></td></tr><tr><td align="center" valign="middle" >合并溃疡</td><td align="center" valign="middle" >14 (29.2)</td><td align="center" valign="middle" >4 (40.0)</td><td align="center" valign="middle" >0.766</td></tr></tbody></table></table-wrap><p>表2. 内镜黏膜下剥离术后阳性切缘患者肿瘤残留或复发的统计学分析</p></sec><sec id="s7_2"><title>3.2. 增加肿瘤残留/复发风险的因素</title><p>通过对两组数据的各自变量的差异性分析，我们发现切缘类型(P = 0.012)、组织分化类型(P = 0.001)以及浸润深度(P = 0.004)与肿瘤残留/复发显著相关(表2)，由此得出基底切缘阳性、较低分化类型、粘膜下浸润可能增加肿瘤残留/复发的风险。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>研究纳入的58例切缘阳性的病例中，ESD术后肿瘤残留/复发率仅为17.2%；而接受外科切除手术的14例患者中仅有半数在手术标本中发现残留肿瘤或淋巴结转移。为减少这种额外的切除性手术，我们试图通过评估胃ESD术后肿瘤切缘阳性患者的残留/复发肿瘤的发生率及临床、病理特征进一步探究增加肿瘤残留/复发的风险的因素。统计分析显示，基底切缘阳性、较低分化类型、粘膜下浸润可能增加肿瘤残留/复发的风险，这与以往类似研究结果一致 [<xref ref-type="bibr" rid="hanspub.41272-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref15">15</xref>]。</p><p>ESD的目的是切缘阴性，但由于各种因素的影响，非预期的阳性切缘难以避免。垂直切缘与水平切缘的临床意义具有一定差异，前期研究发现在81例阳性切缘病灶中，水平切缘阳性其残留病灶性质以癌前病变为主，与术者为缓解术后并发症在剥离范围划定时相对保守有关；而垂直切缘阳性其残留病灶性质多为癌，最近的研究也论证了上述结果 [<xref ref-type="bibr" rid="hanspub.41272-ref16">16</xref>]。基底切缘阳性也是肿瘤术后复发的危险因素之一 [<xref ref-type="bibr" rid="hanspub.41272-ref14">14</xref>]，本研究复发病例数量较少，后期可进行多中心多样本量的研究证明基底切缘阳性对于早期胃癌患者ESD术治疗的远期预后。病变深度判断不准确是基底切缘阳性的主要原因之一。粘膜下病变难以通过常规的内窥镜染色喷涂法确定浸润深度，可应用超声内镜(Endoscopic Ultrasonography, EUS)辅助评估浸润深度；但有研究显示EUS评估肿瘤浸润深度的准确率为80.7%，而在评估粘膜下浸润病变的浸润深度时EUS的准确性降低(42.9%) [<xref ref-type="bibr" rid="hanspub.41272-ref17">17</xref>]。现有内镜检查技术对浸润深度判断难以精准确定垂直切缘，导致ESD手术深度不够，往往造成非预期的病灶残留。因此，基底切缘阳性尤其是粘膜下浸润的病灶，术后发生残留、淋巴结转移及复发的风险较高，建议患者酌情外科手术治疗。</p><p>在2020年日本胃肠病学内窥镜学会/日本胃癌协会最新指南中，将胃癌中高分化或中分化腺癌归类为分化型癌症，而低分化腺癌、印戒细胞癌及粘液腺癌被归类为未分化型癌症。已知未分化型癌症是切缘阳性的独立危险因素 [<xref ref-type="bibr" rid="hanspub.41272-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref20">20</xref>]。并且未分化癌更容易早期侵犯血管和淋巴结或引起深部浸润 [<xref ref-type="bibr" rid="hanspub.41272-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41272-ref21">21</xref>]。本研究中10例残留/复发组患者组织学类型均为未分化癌，与无残留/复发组比较具有显著差异。值得注意的是，印戒细胞癌患者胃内肿瘤多呈弥漫性改变，合并溃疡，形成于粘膜肌层并具有向周围生长的趋势，且常伴有淋巴结转移 [<xref ref-type="bibr" rid="hanspub.41272-ref22">22</xref>]。建议对于ESD术后切缘阳性的病灶，若组织学类型为未分化癌尤其是印戒细胞癌，多伴有残留及淋巴结转移，为改善预后可进一步外科手术治疗。</p><p>10例病灶中除1例eCuraC-1病变于ESD术后随访期间出现复发外，其余9例均归类为eCuraC-2病变。eCuraC-2病变是否需要追加手术，对临床医生仍是一个难题。Hatta等 [<xref ref-type="bibr" rid="hanspub.41272-ref23">23</xref>] 提出的早期胃癌ESD术后eCura危险评分系统将赋予五项指标不同的分值：肿瘤直径(&gt;30 mm 1分)、垂直切缘(1分)、淋巴管浸润(3分)、血管浸润(1分)、浸润深度(SM2 1分)。然后依据评分将患者分为3个淋巴结转移危险组：低(0~1分：2.5%风险)、中(2~4分：6.7%)和高(5~7分：22.7%)，并指出对于低危险患者可考虑术后随访，5年生存率可达99.6%。随后的临床研究显示eCura评分系统是影响肿瘤残留的唯一显著因素：eCura评分越高，越可能发生术后残留 [<xref ref-type="bibr" rid="hanspub.41272-ref24">24</xref>]。李宇新等 [<xref ref-type="bibr" rid="hanspub.41272-ref25">25</xref>] 的临床验证研究指出eCura评分为低危的患者追加外科手术的获益有限，而中、高危患者应追加外科手术以改善预后。然而，本研究中ESD术后发生残留/复发的eCuraC-2病变分别评估为：4例低危、4例中危、1例高危；这与Hatta的评分系统有所矛盾。已知这些病变均为未分化癌，我们认为对于未分化型早期胃癌患者的，eCuraC危险评分并不一定适用。Hatta等 [<xref ref-type="bibr" rid="hanspub.41272-ref26">26</xref>] 的后期比较研究也指出该评分系统对于上述患者的局限性。</p><p>本研究有一定局限性，首先研究设计是回顾性研究，无法统一随访时间，一些由于高龄、严重共患病保守治疗的患者及失访的患者可能会造成一定选择偏倚；其次本研究是基于单中心的研究，且样本量有限，仍需进行多中心的大样本统计分析以评估胃ESD术后肿瘤切缘阳性患者的残留/复发的危险因素及补救性治疗方案。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，内镜下胃粘膜下剥离术后肿瘤切缘阳性患者，推荐应用eCura危险评分系统进行危险分层。若术后病理为基底切缘阳性、未分化组织学类型、粘膜下浸润，提示肿瘤残留/复发的高风险，应结合患者实际情况建议追加外科手术。</p></sec><sec id="s10"><title>文章引用</title><p>梁 越,李 倩,孙 慧,刘福国. 内镜下胃粘膜下剥离术后切缘阳性患者肿瘤残留或复发的回顾性分析Retrospective Analysis of Residual or Recurrence of Tumor in Patients with Positive Margin after Endoscopic Submucosal Gastric Dissection[J]. 临床医学进展, 2021, 11(03): 1301-1308. https://doi.org/10.12677/ACM.2021.113186</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41272-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.41272-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., et al. (2019) Management of Epithelial Precancerous Conditions and Lesions in the Stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) Guideline Update 2019. Endoscopy, 51, 365-388. &lt;br&gt;https://doi.org/10.1055/a-0859-1883</mixed-citation></ref><ref id="hanspub.41272-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">An, L., Gaowa, S., Cheng, H., et al. (2019) Long-Term Outcomes Comparison of Endoscopic Resection with Gastrectomy for Treatment of Early Gastric Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 9, 725.  
&lt;br&gt;https://doi.org/10.3389/fonc.2019.00725</mixed-citation></ref><ref id="hanspub.41272-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lian, J., Chen, S., Zhang, Y., et al. (2012) A Meta-Analysis of Endoscopic Submucosal Dissection and EMR for Early Gastric Cancer. Gastrointestinal Endoscopy, 76, 763-770. &lt;br&gt;https://doi.org/10.1016/j.gie.2012.06.014</mixed-citation></ref><ref id="hanspub.41272-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y. and Wang, C. (2018) Long-Term Clinical Efficacy and Perioperative Safety of Endoscopic Submucosal Dissection versus Endoscopic Mucosal Resection for Early Gastric Cancer: An Updated Meta-Analysis. BioMed Research International, 2018, Article ID: 3152346. &lt;br&gt;https://doi.org/10.1155/2018/3152346</mixed-citation></ref><ref id="hanspub.41272-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ono, H., Yao, K., Fujishiro, M., et al. (2021) Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer (Second Edition). Digestive Endoscopy, 33, 4-20.  
&lt;br&gt;https://doi.org/10.1111/den.13883</mixed-citation></ref><ref id="hanspub.41272-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李焱冬, 张延强, 俞江平, 等. 早期胃癌内镜黏膜下剥离术后追加手术的原因分析[J]. 中国微创外科杂志, 2020, 20(4): 300-303.</mixed-citation></ref><ref id="hanspub.41272-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">李韶华, 谢华红, 幺立萍, 等. 内镜黏膜下剥离术治疗早期胃癌复发及影响因素分析[J]. 临床误诊误治, 2019, 32(9): 58-61.</mixed-citation></ref><ref id="hanspub.41272-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Jun, H., Bae, J.M., Choi, M.G., et al. (2011) Surgical Outcome after Incomplete Endoscopic Submucosal Dissection of Gastric Cancer. British Journal of Surgery, 98, 73-78. &lt;br&gt;https://doi.org/10.1002/bjs.7274</mixed-citation></ref><ref id="hanspub.41272-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bae, S.Y., Jang, T.H., Min, B.H., et al. (2012) Early Additional Endoscopic Submucosal Dissection in Patients with Positive Lateral Resection Margins after Initial Endoscopic Submucosal Dissection for Early Gastric Cancer. Gastrointestinal Endoscopy, 75, 432-436. &lt;br&gt;https://doi.org/10.1016/j.gie.2011.09.044</mixed-citation></ref><ref id="hanspub.41272-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Song, K.Y., Hyung, W.J., Kim, H.H., et al. (2008) Is Gastrectomy Mandatory for All Residual or Recurrent Gastric Cancer Following Endoscopic Resection? A Large-Scale Korean Multi-Center Study. Journal of Surgical Oncology, 98, 6-10. &lt;br&gt;https://doi.org/10.1002/jso.21074</mixed-citation></ref><ref id="hanspub.41272-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kim, H.S., Ahn, J., Kim, S.O., et al. (2017) Can Further Gastrectomy Be Avoided in Patients with Incomplete Endoscopic Resection? Surgical Endoscopy, 31, 4735-4748. &lt;br&gt;https://doi.org/10.1007/s00464-017-5550-9</mixed-citation></ref><ref id="hanspub.41272-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Noh, G.Y., Ku, H.R., Kim, Y.J., et al. (2015) Clinical Outcomes of Early Gastric Cancer with Lymphovascular Invasion or Positive Vertical Resection Margin after Endoscopic Submucosal Dissection. Surgical Endoscopy, 29, 2583-2589. &lt;br&gt;https://doi.org/10.1007/s00464-014-3973-0</mixed-citation></ref><ref id="hanspub.41272-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hatta, W., Gotoda, T., Oyama, T., et al. (2017) Is Radical Surgery Necessary in All Patients Who Do Not Meet the Curative Criteria for Endoscopic Submucosal Dissection in Early Gastric Cancer? A Multi-Center Retrospective Study in Japan. Journal of Gastroenterology, 52, 175-184. &lt;br&gt;https://doi.org/10.1007/s00535-016-1210-4</mixed-citation></ref><ref id="hanspub.41272-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wen, J., Yan, B., Yang, J., et al. (2020) Relevant Risk Factors and the Prognostic Impact of Positive Resection Margins after Endoscopic Resection of Gastrointestinal Neuroendocrine Tumors. Wideochir Inne Tech Maloinwazyjne, 15, 276-282. &lt;br&gt;https://doi.org/10.5114/wiitm.2019.89192</mixed-citation></ref><ref id="hanspub.41272-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">张艳, 张伟, 张莹. 胃癌癌前病变及早期癌内镜黏膜下剥离术后标本切缘阳性危险因素研究[J]. 江苏预防医学, 2020, 31(5): 516-519.</mixed-citation></ref><ref id="hanspub.41272-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Okada, K., Fujisaki, J., Kasuga, A., et al. (2011) Endoscopic Ultrasonography Is Valuable for Identifying Early Gastric Cancers Meeting Expanded-Indication Criteria for Endoscopic Submucosal Dissection. Surgical Endoscopy, 25, 841-848.  
&lt;br&gt;https://doi.org/10.1007/s00464-010-1279-4</mixed-citation></ref><ref id="hanspub.41272-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wen, J., Linghu, E.Q., Yang, Y.S., et al. (2015) Associated Risk Factor Analysis for Positive Resection Margins after Endoscopic Submucosal Dissection in Early-Stage Gastric Cancer. Journal of BUON, 20, 421-427.</mixed-citation></ref><ref id="hanspub.41272-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Numata, N., Oka, S., Tanaka, S., et al. (2015) Risk Factors and Management of Positive Horizontal Margin in Early Gastric Cancer Resected by En Bloc Endoscopic Submucosal Dissection. Gastric Cancer, 18, 332-338.  
&lt;br&gt;https://doi.org/10.1007/s10120-014-0368-9</mixed-citation></ref><ref id="hanspub.41272-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kakushima, N., Ono, H., Tanaka, M., et al. (2011) Factors Related to Lateral Margin Positivity for Cancer in Gastric Specimens of Endoscopic Submucosal Dissection. Digestive Endoscopy, 23, 227-232.  
&lt;br&gt;https://doi.org/10.1111/j.1443-1661.2010.01092.x</mixed-citation></ref><ref id="hanspub.41272-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">钟涛. 从单中心数据分析早期胃癌淋巴结转移的危险因素及内镜非治愈性切除术后追加外科手术的必要性[D]: [硕士学位论文]. 南昌: 南昌大学, 2020.</mixed-citation></ref><ref id="hanspub.41272-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Martinson, H.A., Shelby, N.J., Alberts, S.R., et al. (2018) Gastric Cancer in Alaska Native People: A Cancer Health Disparity. World Journal of Gastroenterology, 24, 2722-2732. &lt;br&gt;https://doi.org/10.3748/wjg.v24.i25.2722</mixed-citation></ref><ref id="hanspub.41272-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hatta, W., Gotoda, T., Oyama, T., et al. (2019) Correction: A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura System”. The American Journal of Gastroenterology, 114, 1925-1926. &lt;br&gt;https://doi.org/10.14309/ajg.0000000000000432</mixed-citation></ref><ref id="hanspub.41272-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Niwa, H., Ozawa, R., Kurahashi, Y., et al. (2018) The eCura System as a Novel Indicator for the Necessity of Salvage Surgery after Non-Curative ESD for Gastric Cancer: A Case-Control Study. PLoS ONE, 13, e0204039.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0204039</mixed-citation></ref><ref id="hanspub.41272-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">李宇新, 孙琦, 郭慧敏, 等. 早期胃癌内镜黏膜下剥离术后eCura危险评分系统的临床验证研究[J]. 中华消化内镜杂志, 2020, 37(6): 409-414.</mixed-citation></ref><ref id="hanspub.41272-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hatta, W., Gotoda, T., Oyama, T., et al. (2018) Is the eCura System Useful for Selecting Patients Who Require Radical Surgery after Noncurative Endoscopic Submucosal Dissection for Early Gastric Cancer? A Comparative Study. Gastric Cancer, 21, 481-489. &lt;br&gt;https://doi.org/10.1007/s10120-017-0769-7</mixed-citation></ref></ref-list></back></article>